A chemotherapy medication provided to adult patients suffering from leukemia is under investigation by the Food and Drug Administration following an increase in the number of adverse event reports filed in association with the product. The drug is called Iclusig and the FDA is concerned about reported incidents in which a patient’s blood vessels became constricted and blood clots formed. These issues could be serious enough that they may lead to a patient fatality. In reports like these and clinical trials, persons have suffered fatal heart attacks and blood flow issues requiring immediate surgery in order to correct. Doctors are being asked to weigh the benefits of Iclusig with the risks described above when determining if a patient should be prescribed the product.
Click here for more information.